Philips Teams up with Visiopharm to Boost Breast Cancer Diagnosis Objectivity Through Computational Pathology
June 21 2016 - 7:05AM
Business Wire
- Breast cancer patients in Europe are
set to benefit from more objective diagnosis
- Philips’ digital pathology offering to
be complemented with Visiopharm breast cancer panel algorithms
Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has
signed a licensing agreement with Visiopharm to offer their breast
cancer panel software algorithms [1] with Philips IntelliSite [2]
digital pathology solution to help pathologists with an objective
diagnosis of breast cancer. Applying smart computer processing to
the digital tumor tissue image, the companies believe that the
pathologist will be able to achieve a more consistent reading and
diagnosis to help inform the patient’s treatment regime.
Visiopharm’s breast cancer panel software (Ki-67 APP for Breast
Cancer, Her2 APP for Breast Cancer, ER APP for Breast Cancer and PR
APP for Breast Cancer) are CE marked for diagnostic use in Europe
[1].
Through strategic investments in R&D, an acquisition,
partnerships and technology licenses, Philips is building a leading
portfolio for the digitization of pathology, a fast-growing area in
healthcare as pathology labs are looking to improve productivity
and enhance quality.
The pathologist plays a critical role in disease detection such
as cancer by examining suspected tissue under a microscope. The
American Society of Clinical Oncology reported [3] that current
HER2 (breast cancer) testing may be inaccurate. Specifically, the
assessment biomarker status of cancerous cells in tissue proved to
be subjective with variability in readings amongst pathologists.
Studies have shown that digital image analysis in support of the
pathologist assessment actually outperform manual biomarker
assessment in this task [4].
“Over the past 150 years, the pathologist has used a traditional
microscope to diagnose cancer and other diseases,” said Visiopharm
CEO Dr. Michael Grunkin. “Rapid advances in digital imaging coupled
with the use of powerful new analytic methods promise to radically
change the future of pathology. Combining the high image quality
from Philips’ IntelliSite pathology solution with Visiopharm’s
reagent agnostic diagnostic image analysis is the first step
towards improving data quality in histopathology.”
Digitization of pathology will open up new ways to get more
information from tissue samples. High quality digital images and
world class image analysis will facilitate the objective analysis
of images. With advanced algorithms and data management systems,
Philips aims to help to translate the big data into actionable
knowledge and equip pathologists with needed tools to enable a more
accurate and precise diagnosis which could help providing more
personalized treatment.
“We are committed to empower pathologists with the best tools to
fight cancer,” said Russ Granzow, General Manager of Philips
Digital Pathology Solutions. “With computational pathology we
continue to innovate with the goal to improve the effectiveness and
quality of cancer diagnosis.”
Philips lntelliSite pathology solution is an automated digital
pathology image creation, management and viewing system comprised
of an ultra-fast pathology slide scanner, an image management
system and dedicated software tools. Across the globe, several
high-volume and networked pathology institutions are relying on the
Philips IntelliSite pathology platform for improved workflows,
enhanced collaboration capabilities and provide new insights that
ultimately could lead to better patient outcomes.
[1] Visiopharm breast cancer panel software (Ki-67 APP for
Breast Cancer, Her2 APP for Breast Cancer, ER APP for Breast Cancer
and PR APP for Breast Cancer) are CE marked for diagnostic use in
Europe. These algorithms are for research use only and not approved
for use in diagnostic procedures in the United States and
Canada.
[2] In the European Union, the Philips IntelliSite Pathology
Solution is CE Marked under the European Union's 'In Vitro
Diagnostics Directive' for in vitro diagnostic use. In Canada, the
Philips IntelliSite Pathology Solution is licensed by Health Canada
for in vitro diagnostic use. In the United States, the Philips
IntelliSite Pathology Solution is indicated for in vitro diagnostic
use for Manual Read of the Digital HER2 Application. The Philips
IntelliSite Pathology Solution is registered for in vitro
diagnostic use in Australia, Singapore and Middle East.
[3] Guideline for HER2 Testing in Breast Cancer—Wolff et al,
Arch Pathol Lab Med—Vol 131, January 2007
[4] Digital image analysis in breast cancer - G Stålhammar et al
Modern Pathology (2016) 29, 318–329
About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people’s health and enabling better outcomes across
the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to
deliver integrated solutions. The company is a leader in
diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as
in consumer health and home care.
Headquartered in the Netherlands, Philips’ health technology
portfolio generated 2015 sales of EUR 16.8 billion and employs
approximately 69,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
About VisiopharmVisiopharm image analysis software has
become the preferred Quantitative Digital Pathology solution for
leading biopharmaceutical companies, contract research
organizations (CRO), research institutions, and for hospital
diagnostic pathology labs around the world. Our software is
featured in over 1000 scientific publications, and is compatible
with leading slide scanner manufacturers, data management software,
and a wide variety of microscopes and cameras. Visiopharm is an
international business with over 600 licenses placed, with
countless users, in more than 35 countries. The company was founded
in 2001 by the Managing Director, and Chief Executive Officer,
Michael Grunkin and the Chief Technical officer, Johan Doré Hansen,
who both have a strong scientific and practical background in image
analysis. See more on www.visiopharm.com/appcenter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160621005195/en/
Philips Digital Pathology SolutionsHans Driessen, +31 6
10610417hans.driessen@philips.comorPhilips Group
CommunicationsSteve Klink, +31 6
10888824steve.klink@philips.comorVisiopharm A/SHelle Fisker, +45
29178777CMOhfi@visiopharm.com
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From May 2023 to May 2024